These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 37760482)

  • 1. The Prognostic Value of the Novel Global Immune-Nutrition-Inflammation Index (GINI) in Stage IIIC Non-Small Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy.
    Topkan E; Selek U; Pehlivan B; Kucuk A; Ozturk D; Ozdemir BS; Besen AA; Mertsoylu H
    Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Value of Novel CARWL Score in Stage IIIC Non-Small-Cell Lung Cancer Patients Undergoing Concurrent Chemoradiotherapy.
    Topkan E; Kucuk A; Ozturk D; Ozkan EE; Besen AA; Pehlivan B; Selek U
    Can Respir J; 2024; 2024():2803044. PubMed ID: 38975012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The global immune-nutrition-inflammation index (GINI) as a robust prognostic factor in glioblastoma patients treated with the standard stupp protocol.
    Topkan E; Kilic Durankus N; Senyurek S; Öztürk D; Besen AA; Mertsoylu H; Pehlivan B; Selek U
    Int J Immunopathol Pharmacol; 2024; 38():3946320241284089. PubMed ID: 39305006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High pre-chemoradiotherapy pan-immune-inflammation value levels predict worse outcomes in patients with stage IIIB/C non-small-cell lung cancer.
    Topkan E; Kucuk A; Ozkan EE; Ozturk D; Besen AA; Mertsoylu H; Pehlivan B; Selek U
    Discov Oncol; 2023 Dec; 14(1):230. PubMed ID: 38091179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Global Immune-Nutrition-Inflammation Index as a novel comprehensive biomarker in predicting the radiation-induced trismus rates in locally advanced nasopharyngeal carcinoma patients.
    Somay E; Topkan E; Bascil S; Kılıc Durankuş N; Senyürek Ş; Ozturk D; Pehlivan B; Selek U
    Biomol Biomed; 2024 Oct; 24(6):1703-1710. PubMed ID: 38860864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significance of overall concurrent chemoradiotherapy duration on survival outcomes of stage IIIB/C non-small-cell lung carcinoma patients: Analysis of 956 patients.
    Topkan E; Ozdemir Y; Kucuk A; Besen AA; Mertsoylu H; Sezer A; Selek U
    PLoS One; 2019; 14(7):e0218627. PubMed ID: 31329602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low Prognostic Nutritional Index Predicts Poor Clinical Outcomes in Patients with Stage IIIB Non-small-cell Lung Carcinoma Undergoing Chemoradiotherapy.
    Ozdemir Y; Topkan E; Mertsoylu H; Selek U
    Cancer Manag Res; 2020; 12():1959-1967. PubMed ID: 32214853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic immune-inflammation index changes predict outcome in stage III non-small-cell lung cancer patients treated with concurrent chemoradiotherapy.
    Huang T; Zhang H; Zhao Y; Li Y; Wang G; Zhang Y; Guo D; Ji S; Sun Z
    Future Oncol; 2021 Jun; 17(17):2141-2149. PubMed ID: 33635094
    [No Abstract]   [Full Text] [Related]  

  • 9. The effect of tumor volume and its change on survival in stage III non-small cell lung cancer treated with definitive concurrent chemoradiotherapy.
    Koo TR; Moon SH; Lim YJ; Kim JY; Kim Y; Kim TH; Cho KH; Han JY; Lee YJ; Yun T; Kim HT; Lee JS
    Radiat Oncol; 2014 Dec; 9():283. PubMed ID: 25498887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Somay's GLUCAR Index Efficiently Predicts Survival Outcomes in Locally Advanced Pancreas Cancer Patients Receiving Definitive Chemoradiotherapy: A Propensity-Score-Matched Cohort Analysis.
    Topkan E; Senyurek S; Kılic Durankus N; Ozturk D; Selek U
    J Pers Med; 2024 Jul; 14(7):. PubMed ID: 39064000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Usefulness Of Advanced Lung Cancer Inflammation Index In Locally-Advanced Pancreatic Carcinoma Patients Treated With Radical Chemoradiotherapy.
    Topkan E; Mertsoylu H; Ozdemir Y; Sezer A; Kucuk A; Besen AA; Ozyilkan O; Selek U
    Cancer Manag Res; 2019; 11():8807-8815. PubMed ID: 31632140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Planning target volume as a predictor of disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibition.
    Taugner J; Käsmann L; Karin M; Eze C; Flörsch B; Guggenberger J; Li M; Tufman A; Reinmuth N; Duell T; Belka C; Manapov F
    Invest New Drugs; 2022 Feb; 40(1):163-171. PubMed ID: 34351518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of neutrophil-to-lymphocyte ratio in locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
    Park EY; Kim YS; Choi KH; Song JH; Lee HC; Hong SH; Kang JH
    Radiat Oncol J; 2019 Sep; 37(3):166-175. PubMed ID: 31591864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor angiogenesis at baseline identified by
    Wei Y; Qin X; Liu X; Zheng J; Luan X; Zhou Y; Yu J; Yuan S
    J Transl Med; 2022 Feb; 20(1):63. PubMed ID: 35109866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic role of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in patients with stage III non-small cell lung cancer treated with concurrent chemoradiotherapy.
    Yılmaz U; Ozdemir O; Batum O; Ermin S
    Indian J Cancer; 2018; 55(3):276-281. PubMed ID: 30693894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baseline Low Prognostic Nutritional Index Predicts Poor Survival in Locally Advanced Nasopharyngeal Carcinomas Treated With Radical Concurrent Chemoradiotherapy.
    Topkan E; Yucel Ekici N; Ozdemir Y; Besen AA; Mertsoylu H; Sezer A; Selek U
    Ear Nose Throat J; 2021 Feb; 100(2):NP69-NP76. PubMed ID: 31184210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy profiles of concurrent chemoradiotherapy with intensity-modulated radiotherapy followed by durvalumab in patients with unresectable stage III non-small cell lung cancer: A multicenter retrospective cohort study.
    Takeda Y; Kusaba Y; Tsukita Y; Uemura Y; Miyauchi E; Yamamoto T; Mayahara H; Hata A; Nakayama H; Tanaka S; Uchida J; Usui K; Toyoda T; Tamiya M; Morimoto M; Oya Y; Kodaira T; Jingu K; Sugiura H
    Clin Transl Radiat Oncol; 2022 Nov; 37():57-63. PubMed ID: 36065360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of pretreatment Glasgow prognostic score in stage IIIB geriatric non-small cell lung cancer patients undergoing radical chemoradiotherapy.
    Topkan E; Bolukbasi Y; Ozdemir Y; Besen AA; Mertsoylu H; Selek U
    J Geriatr Oncol; 2019 Jul; 10(4):567-572. PubMed ID: 31178158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive value of post-treatment C-reactive protein-to-albumin ratio in locally advanced non-small cell lung cancer patients receiving durvalumab after chemoradiotherapy.
    Araki T; Tateishi K; Komatsu M; Sonehara K; Wasamoto S; Koyama S; Yoshiike F; Hama M; Nishie K; Kondo D; Agatsuma T; Kato A; Takata M; Kanda S; Hanaoka M; Koizumi T
    Thorac Cancer; 2022 Jul; 13(14):2031-2040. PubMed ID: 35616056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing Survival of Patients With Marginally Operable Stage IIIA Non-Small-Cell Lung Cancer Receiving Chemoradiotherapy With or Without Surgery.
    Yang KL; Chang YC; Ko HL; Chi MS; Wang HE; Hsu PS; Lin CC; Yeh DY; Kao SJ; Jiang JS; Chi KH
    Clin Lung Cancer; 2016 Nov; 17(6):550-557. PubMed ID: 27378175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.